Teriparatide News and Research

RSS

Injectable osteoporosis drug can be safely administered orally using a novel 'robotic pill'

A proven and effective medication for osteoporosis, which is currently only available as an injection, can be administered orally using a novel "robotic pill," according to a study presented Saturday at ENDO 2023, the Endocrine Society's annual meeting in Chicago, Ill.

18 Jun 2023

Osteoporosis drug increases bone mineral density in the hip and lumbar spine

New research presented at ACR Convergence, the American College Rheumatology's annual meeting, reveals that romosozumab, an osteoporosis drug, produces substantial gains in bone mineral density in the hip and lumbar spine within one year, and that transitioning patients to a potent antiresorptive drug can lead to even more bone density gains.

6 Nov 2020

New guidance released for treating patients with osteoporosis during COVID-19 crisis

The Endocrine Society joined a coalition of leading bone health organizations to release guidance for healthcare professionals treating patients with osteoporosis in the era of COVID-19.

8 May 2020

GlobalData highlights low diagnosis and treatment rates of osteoporosis

As World Osteoporosis Day approaches (20 October), it marks a year-long campaign dedicated to raising global awareness of this bone disease. A major unmet need in this space is the low rate of diagnosis and treatment.

18 Oct 2019

$Drug holiday from bisphosphonates for more than two years linked to higher hip fracture risk in women$

Drug holiday from bisphosphonates for more than two years linked to higher hip fracture risk in women

Women who took a drug holiday (temporary or permanent discontinuation of a medicine) from using bisphosphonates for more than two years have a significantly higher risk of a hip fracture compared to others who continued their treatment, according to new research findings presented this week at the 2017 ACR/ARHP Annual Meeting in San Diego.

6 Nov 2017

ACR’s updated guideline provides recommendations on treatment of glucocorticoid-induced osteoporosis

The American College of Rheumatology's updated clinical guideline for the prevention and treatment of glucocorticoid-induced osteoporosis is now available online.

7 Jun 2017

New guidelines recommend evaluation of osteoporosis risk for all postmenopausal women

Osteoporosis is preventable and treatable, but only a small proportion of people at risk for fractures are evaluated and treated, according to new osteoporosis guidelines written by an expert panel headed by Loyola Medicine endocrinologist Pauline M. Camacho, MD, FACE.

30 Nov 2016

$Already available drug accelerates healing process after hip fracture$

Already available drug accelerates healing process after hip fracture

An already available drug can help patients get back on their feet more rapidly after a hip fracture, according to an international study published in the Journal of Bone Joint Surgery.

21 Nov 2016

Molecular signaling pathway could be basis of potential new treatment for osteoporosis

A molecular signaling pathway identified by an international research team could be the basis of improved treatment for osteoporosis.

19 Oct 2016

$New review shows both types of diabetes increase risk of fragility fractures$

New review shows both types of diabetes increase risk of fragility fractures

Recent research has shown that bone health is compromised in people with diabetes, resulting in a significantly higher risk of fragility fracture.

4 Oct 2016

$Multidisciplinary experts assess effects of osteoporosis drugs on fracture healing$

Multidisciplinary experts assess effects of osteoporosis drugs on fracture healing

In people with osteoporosis, one fracture often leads to more fractures, and potentially a future of pain, disability, and poor quality of life. While studies have shown that such high-risk patients benefit from appropriate medication to reduce future fracture risk, more research is needed on the effect of osteoporosis medications on fracture healing.

28 Apr 2016

Investigational drug abaloparatide-SC may help increase bone mineral density in postmenopausal women

The investigational drug abaloparatide-SC (subcutaneous) may help increase bone mineral density in postmenopausal women and reduce their risk of fracture, new industry-sponsored research suggests. The results of the subgroup analysis within the ACTIVE clinical trial will be presented Friday, April 1, at ENDO 2016, the annual meeting of the Endocrine Society in Boston.

4 Apr 2016

$Combination of adult stem cells and parathyroid hormone may speed healing process for bone fractures$

Combination of adult stem cells and parathyroid hormone may speed healing process for bone fractures

A combination of adult stem cells and parathyroid hormone significantly increased new bone formation in laboratory animals and may speed the healing process for human bone fractures caused by osteoporosis, a new study shows.

9 Dec 2015

Data shows romosozumab better than teriparatide in increasing bone strength in postmenopausal women

Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today presented additional findings from an exploratory sub-study of the previously reported romosozumab Phase 2 trial.

13 Oct 2015

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

Glide Technologies, the development company focused on solid dose formulations of therapeutics and vaccines and non-invasive diagnostics, today announced that its novel solid dose formulation of teriparatide (parathyroid hormone) achieved successful results in a pre-clinical proof-of-concept study comparing it with the currently marketed liquid product (Forteo/Forsteo).

24 Apr 2015

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

24 Apr 2015

$Investigational drug for postmenopausal osteoporosis reduces rate of new spinal fractures$

Investigational drug for postmenopausal osteoporosis reduces rate of new spinal fractures

Abaloparatide-SC, an injectable drug being studied for the treatment of postmenopausal osteoporosis, reduces the rate of new spinal fractures by a statistically significant 86 percent and as well as statistically significant reductions in the fracture rate at other parts of the body, a phase 3 clinical trial finds. Results of the ACTIVE fracture prevention trial will be described in a late-breaking oral presentation Thursday at the Endocrine Society's 97th annual meeting in San Diego.

9 Mar 2015

$New guidance to prevent bisphosphonate-related atypical femoral fractures$

New guidance to prevent bisphosphonate-related atypical femoral fractures

Physicians worldwide frequently prescribe bisphosphonates such as alendronate (Fosamax) and ibandronate (Boniva) to treat osteoporosis and prevent fragility fractures. Unfortunately, long-term bisphosphonate use has been linked to an increased risk of atypical femoral fractures.

4 Mar 2015

New approach promises better drugs for diabetes and osteoporosis

By swapping replacement parts into the backbone of a synthetic hormone, UW-Madison graduate student Ross Cheloha and his mentor, Sam Gellman, along with collaborators at Harvard Medical School, have built a version of a parathyroid hormone that resists degradation in laboratory mice.

18 Jun 2014

Amgen announces romosozumab Phase 2 trial results in postmenopausal women with low BMD

Amgen and UCB (Euronext Brussels:UCB) today announced results from a Phase 2 trial evaluating romosozumab (AMG 785/CDP7851) in postmenopausal women with low bone mineral density (BMD).

2 Jan 2014

Teriparatide News and Research

Injectable osteoporosis drug can be safely administered orally using a novel 'robotic pill'

Osteoporosis drug increases bone mineral density in the hip and lumbar spine

New guidance released for treating patients with osteoporosis during COVID-19 crisis

GlobalData highlights low diagnosis and treatment rates of osteoporosis

Drug holiday from bisphosphonates for more than two years linked to higher hip fracture risk in women

ACR’s updated guideline provides recommendations on treatment of glucocorticoid-induced osteoporosis

New guidelines recommend evaluation of osteoporosis risk for all postmenopausal women

Already available drug accelerates healing process after hip fracture

Molecular signaling pathway could be basis of potential new treatment for osteoporosis

New review shows both types of diabetes increase risk of fragility fractures

Multidisciplinary experts assess effects of osteoporosis drugs on fracture healing

Investigational drug abaloparatide-SC may help increase bone mineral density in postmenopausal women

Combination of adult stem cells and parathyroid hormone may speed healing process for bone fractures

Data shows romosozumab better than teriparatide in increasing bone strength in postmenopausal women

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

Investigational drug for postmenopausal osteoporosis reduces rate of new spinal fractures

New guidance to prevent bisphosphonate-related atypical femoral fractures

New approach promises better drugs for diabetes and osteoporosis

Amgen announces romosozumab Phase 2 trial results in postmenopausal women with low BMD

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News